| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
Ankaflavin (0-50 µg/mL, 48 h) exhibits cytotoxicity towards cancer cells, but normal cells are not significantly harmed [1]. Ankaflavin (0-30 µg/mL, 0-48 hours) in a dose- and time-dependent way stops the Hep G2 cell cycle in the sub-G1 phase [1]. In Hep G2 cells, ankaflavin (25 µg/mL, 48 h) causes apoptosis[1].
|
|---|---|
| ln Vivo |
Ankaflavin (10 mg/kg; oral; given once daily for 28 days) may enhance pancreatic and liver function in addition to its antidiabetic and anti-inflammatory properties [2].
|
| Cell Assay |
Cytotoxicity assay[1]
Cell Types: A549, Hep G2, MRC-5 and WI-38 Tested Concentrations: 1, 10, 25 and 50 µg/mL Incubation Duration: 48 hrs (hours) Experimental Results: Shows cytotoxicity against A549 and Hep G2 cells No significant toxicity to normal cells (MRC-5 and WI-38) in a dose-dependent manner. Cell cycle analysis[1] Cell Types: Hep G2 Cell Tested Concentrations: 15, 20, 25 and 30 µg/mL Incubation Duration: 12, 24, 36 and 48 hrs (hours) Experimental Results: Induction of clear sub-G1 peak in Hep G2 cells at dose and time-dependent manner. Apoptosis analysis[1] Cell Types: Hep G2 Cell Tested Concentrations: 25 µg/mL Incubation Duration: 48 hrs (hours) Experimental Results: Hoechst staining shows significant chromatin condensation (fluorescent spots). |
| Animal Protocol |
Animal/Disease Models: Wistar rats (4 weeks old), treated with methylglyoxal (MG) (600 mg/kg; oral) for 4 weeks to induce diabetes [2]
Doses: 10 mg/kg Route of Administration: Oral administration 28-day Experimental Results: PPARγ agonist activity exerted. Effectively reduces AGE (advanced glycation end products) levels in serum, liver and pancreas of MG-induced rats. |
| References |
|
| Additional Infomation |
Ankaflavin has been reported in Monascus pilosus and Monascus purpureus with data available.
|
| Molecular Formula |
C23H30O5
|
|---|---|
| Molecular Weight |
386.4813
|
| Exact Mass |
386.209
|
| CAS # |
50980-32-0
|
| PubChem CID |
15294091
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.15±0.1 g/cm3(Predicted)
|
| Boiling Point |
590.7±50.0 °C(Predicted)
|
| LogP |
4.223
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
28
|
| Complexity |
757
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CCCCCCCC(=O)[C@@H]1[C@H]2CC3=C(COC(=C3)/C=C/C)C(=O)[C@@]2(OC1=O)C
|
| InChi Key |
AQTJNEHGKRUSLT-ODTNPMSZSA-N
|
| InChi Code |
InChI=1S/C23H30O5/c1-4-6-7-8-9-11-19(24)20-18-13-15-12-16(10-5-2)27-14-17(15)21(25)23(18,3)28-22(20)26/h5,10,12,18,20H,4,6-9,11,13-14H2,1-3H3/b10-5+/t18-,20+,23-/m1/s1
|
| Chemical Name |
(3S,3aR,9aR)-9a-methyl-3-octanoyl-6-[(E)-prop-1-enyl]-3,3a,4,8-tetrahydrofuro[3,2-g]isochromene-2,9-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5875 mL | 12.9373 mL | 25.8746 mL | |
| 5 mM | 0.5175 mL | 2.5875 mL | 5.1749 mL | |
| 10 mM | 0.2587 mL | 1.2937 mL | 2.5875 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
